European Commission Approves Tremfya® (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
- EMEA Innovative Medicine
- European Commission Approves Tremfya® (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
European Commission Approves Tremfya® (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis In The European Union
- X (Twitter)
Copy link